

The main training course is designed to provide summaries of the most relevant knowledge on HPV infection and associated diseases with the aim of assisting physicians and educators. The topics covered range from the basic science fundamentals to emerging issues and the clinical uses of screening technologies, prophylactic HPV vaccines and extending to HPV-related diseases in external genitalia and head & neck. Speakers will present only accepted evidence-based scientific information that has been published in the peer-reviewed medical literature.

MAIN TRAINING COURSE - MTC

MTC 1 From infection to diseases at different anatomic sites		Main Auditorium	
Chair: S. Franceschi		9:00 – 10:30	
MTC 1-1	- HPV related cancers: the comparative figures	S. Franceschi	France
MTC 1-2	- Epidemiology, transmission & natural history	A. Giuliano	USA
MTC 1-3	- The biology of HPV infection at different epithelial sites	J. Doorbar	UK
MTC 1-4	- HPV immunology: an update	S. Pai	USA
	- Discussion		
Coffee Break		10:30 – 11:00	
MTC 2 New strategies & innovations in cervical cancer control		Main Auditorium	
Chair: X. Bosch		11:00 – 12:45	
MTC 2-1	- New standards for HPV-based cervical cancer screening	E. Franco	Canada
MTC 2-2	- HPV prophylactic vaccines: lessons learned from 10 years experiences	J. Brotherton	Australia
MTC 2-3	- Integrating primary & secondary prevention: new strategies for cervical cancer control LIC vs HIC	P. Gravitt	USA
MTC 2-4	- Challenges facing novel HPV multivalent vaccine	E. Joura	Austria
MTC 2-5	- The expectancy of HPV therapeutic vaccine	M. Stanley	UK
	- Discussion		
MTC 3 Management of HPV cervical diseases - the state of the art		Main Auditorium	
Chair: W. Kinney		14:30 – 16:00	
MTC 3-1	- The risk-based management	M. Stoler	USA
MTC 3-2	- Triage options of HPV+ women	C. Meijer	Netherlands
MTC 3-3	- Triage strategies of abnormal cytology	W. Kinney	USA
MTC 3-4	- Post-treatment surveillance options	M. Arbyn	Belgium
	- Discussion		
Coffee Break		16:00 – 16:30	
MTC 4 HPV-associated diseases in non-cervical sites - what the clinician should know		Main Auditorium	
Chair: A. Giuliano - M. Gillison		16:30 – 18:00	
MTC 4-1	- Comparative epidemiology and HPV transmission by gender	A. Giuliano	USA
MTC 4-2	- Current developments on HPV-caused oropharyngeal cancer	M. Gillison	USA
MTC 4-3	- Clinical issues related to anal HPV infection and cancer	C. Fairley	Australia
MTC 4-4	- HPV-associated OPC cancer, the state of the art	R. Brakenhoff	Netherlands
MTC 4-5	- The potential of HPV prophylactic & therapeutic vaccines	M. Brisson	Canada
	- Discussion		



JE 1	Curso de Colposcopia Moderador : R. Comino - Director: JC Martínez Escoriza	Auditorium 2 9:30 - 11:15
JE 1-1	- Imágenes Normales	D. Dexeus
JE 1-2	- Imágenes Anormales	F. Coloma
JE 1-3	- La colposcopia en el contexto de los modelos de cribado actuales	M. Cararach
JE 1-4	- Análisis crítico de la Clasificación Colposcópica de Rio de Janeiro 2012	J.C. Martínez Escoriza
JE 1-5	- Casos Clínicos	J.C. Martínez Escoriza J.A. Monserrat
JE 2	Verrugas Genitales/Cribado/Consenso Moderador: R. Comino	Auditorium 2 11:15 - 13:00
JE 2-1	- Verrugas Genitales: Estudio Multicéntrico Español	J. de la Fuente
JE 2-2	- Situación de la Prevención Primaria del Cáncer de Cuello de Útero en España: Fases IV.	M. Brotons
JE 2-3	- Presentación del Documento de Consenso de Prevención del Cáncer de Cuello de Útero en España 2014: Consenso SEGO-AEPC-SEAP-SEC. - Debate	A. Torné
JE 3	Equidad asistencial: de la oncoguía a la practica clínica Moderador: J. Ponce	Auditorium 2 14:30 - 16:25
JE 3-1	- Epidemiología en España de los tumores del Tracto Genital Inferior VPH relacionados	L. Bruni
JE 3-2	- Estrategia y metodología del programa OncoGuías SEGO 2008-2016	M. Cusidó
JE 3-3	- OncoGuía Prevención Secundaria del Cáncer de Cuello de Útero	M. del Pino
JE 3-4	- OncoGuía Cáncer Invasor de Cuello de Útero 2013	L. Martí
JE 3-5	- Caso clínico interactivo: Cáncer de Cuello de Útero	A. Boldo
JE 3-6	- OncoGuía Cáncer Escamoso Invasor de Vulva 2015	J. Lombardía
JE 3-7	- Caso clínico interactivo: Cáncer de Vulva	S. Alonso Salvador
Coffee Break		16:25 - 17:00
JE 4	Técnica quirúrgica en el cáncer de cuello uterino Moderador: A. Sánchez del Rio	Auditorium 2 17:00 - 18:00
JE 4-1	- Histerectomía Radical. Anatomía quirúrgica (video)	J.C. Muruzábal
JE 4-2	- Linfadenectomía pélvica y ganglio centinela (video)	A. Gil
JE 4-3	- Linfadenectomía aorto-cava pre y transperitoneal (video)	M. Barahona
JE 4-4	- Efectividad de la robótica en España. Encuesta Nacional ROBOCER 2014	J. Ponce
JE 5	La educación en el médico de cabecera en el VPH Moderadores: E. Redondo - I. Jimeno En colaboración con SEMERGEN, SEMG	Auditorium 2 18:00 - 19:00
JE 5-1	- La Educación en VPH del Médico Generalista	J. Alonso
JE 5-2	- El papel del Médico Generalista en la Prevención Primaria y Secundaria del Cáncer de Cérnix	A. Cano

ORAL COMMUNICATIONS - OC

OC 1 HPV testing 1		Auditorium 3	
Chair: C. Clavel - M. Einstein		9:00 – 10:30	
OC 1-1	- Detection of cervical disease with the Aptima HPV and cobas 4800 HPV assays using SurePath liquid cytology specimens	M. Chernesky	Canada
OC 1-2	- Direct genotyping from the Aptima® HPV assay using Anyplex™ II HPV28	G. Lillsunde Larsson	Sweden
OC 1-3	- Comparison of HC2 and cobas RealTime PCR in routine HPV testing	H. Ikenberg	Germany
OC 1-4	- Definitive separation of high grade from low grade dysplasia using the combined morphological and molecular biomarkers of OncoTect 3Dx	A. Chargin	USA
OC 1-5	- A novel, simple and specific test for HPV-induced neoplasia via direct detection of E6 oncoprotein	J. Schweizer	USA
OC 1-6	- Performance of the trovagene urine HPV assay in a referral population	J. Cuzick	UK
OC 1-7	- Automated versus manual pre-processing of SurePath liquid-based cytology specimens: assessing impact on the performance of the RealTime high risk HPV assay	A. Sargent	UK
OC 1-8	- Introduction of Cepheid® HPV tests into cervical screening in Malawi	H. Cubie	UK
OC 1-9	- GynTect® a triage test for high-risk human papillomavirus DNA-positive women, may have prognostic potential	M. Schmitz	Germany
OC 1-10	- Validation of Novaprep HQ+ liquid-based cytology media for HR HPV detection by Hybrid Capture 2 (HC2)	J.L. Prêtet	France
OC 1-11	- Validation of two methods of collecting information on HPV test: electronic clinical history and manual register on cervical cancer screening in Spain.	V. Rodriguez-Sales	Spain
OC 1-12	- High-risk HPV mRNA in relation to future high-grade lesions among HPV DNA positive women with minor cytological abnormalities)	O. Forslund	Sweden
Coffee Break		10:30 – 11:00	
OC 2 Epidemiology & natural history 1		Auditorium 3	
Chair: I. Baussano - G. Ogilvie		11:00 – 12:45	
OC 2-1	- Monitoring the impact of the HPV vaccination program and cervical cancer control in Bhutan	I. Baussano	France
OC 2-2	- Possible hand-genital HPV infection transmission among heterosexual couples: results from the HITCH study	K. Louvanto	Canada
OC 2-3	- Availability of type-specific data on HPV infection in Europe for healthy women and women with cervical, vulvar or vaginal disease	T. Weiss	USA
OC 2-4	- Correlation of viral load and persistence for HPV16 and HPV18 in a Dutch cohort of young women	P. Rog	Netherlands
OC 2-5	- Serial type-specific human papillomavirus load predicts histological outcome	S. Verhelst	Belgium
OC 2-6	- The effect of male circumcision on genital HPV infection and external genital lesions in the HIM study	G. Albero	Spain
OC 2-7	- What can twin studies tell us about the aetiology of cervical cancer?	S. Garland	Australia
OC 2-8	- 48 month incident HPV infection rates for women HPV negative at baseline: the HPV focal trial	G. Ogilvie	Canada
OC 2-9	- Trends of hospital diagnostic demand of papillomavirus. 1996-2013	R. Ortiz de Lejarazu	Spain
OC 2-10	- Epidemiology of HPV 6, 11, 16, 18 antibodies among adults in the United States across six years: NHANES 2005-2010	H. Velasco-Mondragon	USA
OC 2-11	- Abundance of putatively novel HPV types identified in eyebrows using novel CODEHOP primers and a single tube nested 'hanging droplet' PCR	B. Kocjan	Slovenia

ORAL COMMUNICATIONS - OC

OC 3 Vaccine 1 (Impact)

Chair: D. Mesher - P. Sparen

Auditorium 3

14:15 - 16:00

OC 3-1	- Significant reduction in the incidence of genital warts in young women and men 5 years into the Danish national HPV vaccination program	B. Baldur-Felskov	Denmark
OC 3-2	- Effectiveness of quadrivalent HPV vaccine on genital warts in a real-life setting in Belgium	G. Dominiak-Felden	France
OC 3-3	- Effect of timing of second dose of quadrivalent HPV-vaccine on condyloma incidence	F. Lamb	Sweden
OC 3-4	- Quadrivalent HPV-vaccine effectiveness against cervical lesions: population-based study	P. Sparen	Sweden
OC 3-5	- HPV vaccination in young women at 25 years in Italy. Efficacy, immunogenicity and impact on screening for cervical cancer	F. Carozzi	Italy
OC 3-6	- Monitoring the impact of the HPV vaccination program in Rwanda	G. Clifford	France
OC 3-7	- Effect of catch up vaccination on HPV prevalence in routine cervical screening	G. Baxter	UK
OC 3-8	- Projecting the potential public health impact of a universal vaccination programme with a nine-valent HPV vaccine in the United Kingdom	T. Nikoglou	France
OC 3-9	- Characteristics of a cluster-randomized, phase IV HPV vaccination effectiveness trial	M. Lehtinen	Finland

Coffee Break

16:00 - 16:30

OC 4 Vaccine 2 (Effectiveness & safety)

Chair: M. Lehtinen - K. Canfell

Auditorium 3

16:30 - 18:30

OC 4-1	- Evidence of cross protection following use of bivalent HPV vaccine in the national HPV immunisation programme in England	D. Mesher	UK
OC 4-2	- Two or three doses for primary HPV vaccination schedules? Systematic review and meta-analysis	N. Low	Switzerland
OC 4-3	- Effectiveness of 3 versus 2 doses of quadrivalent HPV-vaccine on incidence of cervical lesions in a 3-dose vaccination schedule: a population-based study in Denmark and Sweden	S. Kjaer	Denmark
OC 4-4	- Memory B cell responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 year old girls receiving Cervarix® or Gardasil® vaccine	A. Godi	UK
OC 4-5	- Cell-mediated immune response after HPV vaccination	A. Gonçalves	Brazil
OC 4-6	- The effect of herd immunity in different human papillomavirus vaccination strategies: an economic evaluation of the best II study	K. Haeussler	Italy
OC 4-7	- Comparison of safety statements from national authorities and international health bodies for HPV vaccine	R. Konno	Japan
OC 4-8	- The impact of natural immunity on the effectiveness of HPV vaccination	S. Matthijsse	Netherlands
OC 4-9	- Long-term effectiveness of Gardasil™ among adult women in Colombia	R. Das	USA
OC 4-10	- A phase II study of Gardasil in human papillomavirus research: the mid-adult male vaccine study—the MAM study	A. Giuliano	USA



WACC FORUM & HEALTH EDUCATION

BENEFITS AND LIMITATIONS OF INCREASINGLY INFORMED PATIENTS

Sharing knowledge and education for cervical cancer prevention

The WACC Forum (February 4) is organized by the Women Against Cervical Cancer (WACC) Network which represents more than 50 associations from many different countries working for the benefit of womens' health and involved in cervical cancer prevention.

This conference gathers players in the public health education sector from a number of countries, to share experiences on effective communication and learning tools aimed to increase HPV disease awareness and patient education towards active prevention.

W 1	Anti-vaccine movements: tactics and solutions	Madrid Room	
	Chair: M. Steben	10:00 – 13:00	
W 1-1	- Lecture: The science facts about adverse events & HPV vaccines	S. Garland	Australia
W 1-2	- Understanding the tricks and tropes of the antivaccinologists	M. Steben	Canada
W 1-3	- Crisis management: do we need to answer all attacks of antivaccinologists?	E. Bravo	Spain
W 1-4	- Are all experts banned from sharing their knowledge because of collaboration with the industry?	C. Meijer	Netherlands
W 1-5	- Composition of expert teams involved in health technology assessment and decision-making in the field of cervical cancer prevention and potential conflict of interest - the example of Belgium	M. Arbyn	Belgium
W 1-6	- Research on attitudes and acceptance of HPV vaccine	J. Waller	UK
W 1-7	- Helping community groups in their communication activities	J. Smith	USA
	- Questions and comments from the audience		
W 2	Patient survivors' voices: what they want	Madrid Room	
	Chair: J. Smith	14:30 – 16:00	
	- Information : transmission, risk of cancer, protection		
W 2-1	- Cervical cancer	P. Gravitt	USA
W 2-2	- Anal cancer	M. Bower	UK
W 2-3	- Oropharyngeal cancer	C. Fakhry	USA
W 2-4	- The interface between science and policy for global cervical cancer control?	Y.L.Qiao	China
W 2-5	- Print media coverage of the link between HPV and oral cancer in the UK	J. Waller	UK
W 2-6	- Current knowledge about the diseases and best standard of care	W. Huh	USA
W 2-7	- End with the disparity	G. Ogilvie	Canada
W 2-8	- HPV vaccination in Europe: multidisciplinary approach: gynecologists, pediatricians, GP's, Public Health providers	F. Martinon-Torres	Spain

Coffee Break

16:00 – 16:30

ORAL COMMUNICATIONS - OC

OC 5 WACC

Chair: F. Martinon-Torres - J. Waller

Madrid Room

16:30 - 18:30

OC 5-1	- Understanding cervical screening non-attendance among ethnic minority women	L. Marlow	UK
OC 5-2	- Barriers to and facilitators of compliance with clinical based cervical cancer screening	E. Östenson	Sweden
OC 5-3	- Small scale screening – working beside communities to create a sustainable solution to cervical cancer screening in the Peruvian Amazon	G. Shannon	Peru
OC 5-4	- Acceptance and satisfaction of cervical cancer screening program using visual inspection with acetic acid among women in Morocco	F. Selmouni	Morocco
OC 5-5	- Awareness of human papillomavirus before and after introduction of HPV vaccination: a large population-based survey of Scandinavian women	L. Thomsen	Denmark
OC 5-7	- Web-based survey on knowledge for cervical cancer prevention among young women: comparison in Japan and Australia	E. Miyagi	Japan
OC 5-8	- Knowledge and prevalence of HPV diseases in Latvia	D. Rezeberga	Latvia
OC 5-9	- A population based survey of school nurses' attitudes to the implemented HPV vaccination programme in Sweden	M. Grandahl	Sweden
OC 5-10	- Hungarian high school students' attitude toward the HPV vaccine	B. Balla	Hungary
OC 5-11	- Primary prevention of HPV infections for adolescents (education and vaccination)	D. Lepusic	Croatia
OC 5-12	- HPV vaccine concerns in Japan – public health and scientific background	S. Hanley	Japan
OC 5-13	- HPV vaccine concerns in Japan – social and political background	R. Konno	Japan
OC 5-14	- Correlates of uptake in school-based routine HPV vaccination: a register-based study of 90,000 girls and their parents	B. Hansen	Norway
OC 5-15	- Acceptability of 2- versus 3-dose HPV vaccination among vaccine providers and mothers of adolescent girls in five countries	S. Smith	USA

MAIN SCIENTIFIC SESSIONS - MSS

MSS 1 How to introduce HPV testing into primary screening?

Chair: J. Dillner - H. Lawson

Main Auditorium

8:15 - 9:45

MSS 1-1	- Do the current criteria for the recommendation of new HPV tests for cervical cancer screening need to be refined ?	T. Iftner	Germany
MSS 1-2	- Cotesting vs primary standalone HPV testing	H. Lawson	USA
MSS 1-3	- What test to use, is genotyping important?	J. Cuzick	UK
MSS 1-4	- Ages for HPV screening: when to start, when to stop?	E. Franco	Canada
MSS 1-5	- What to do if HPV negative? Interval of screening	J. Dillner	Sweden
MSS 1-6	- Impact of vaccination on primary HPV screening	X. Bosch	Spain
	- Discussion		

MSS 2 Surveillance and impact of HPV prophylactic vaccines in population: current picture

Chair: J. Brotherton

Main Auditorium

9:45 - 11:30

MSS 2-1	- Vaccine uptake across the world	P. Bloem	Switzerland
MSS 2-2	- Monitoring impact in population	D. Mesher	UK
MSS 2-3	- Worldwide surveillance of HPV vaccination coverages: the current picture	L. Bruni	Spain
	- Changes in disease prevalence in vaccinated women		
MSS 2-4	- Genital warts	P. Sparen	Sweden
MSS 2-5	- Cervical diseases	J. Brotherton	Australia
MSS 2-6	- Cancer registries: up to the task of monitoring post vaccination reductions in HPV-related cancers?	F. Bray	France
MSS 2-7	- Monitoring of RRP in the post vaccine era	P. Campisi	Canada
MSS 2-8	- Long-term efficacy of HPV vaccination against hard endpoints	J. Paavonen	Finland
	- Discussion		

CLINICAL SESSIONS - CS

CS 1 Clinical advances & modern management of vulvar carcinoma

Chair: C. Haie-Meder - M. Roy

Auditorium 2

8:30 - 10:00

CS 1-1	- Current knowledge on burden, epidemiology & carcinogenesis	A. Tristram	UK
CS 1-2	- Human papillomavirus genotype attribution for HPV5 6, 11, 16, 18, 31, 33, 45, 52, 58 in female anogenital cancers.	S. De Sanjosé	Spain
CS 1-3	- The contribution of sentinel lymph node detection & new development in vulvar cancer surgery	A. van der Zee	Netherlands
CS 1-4	- What remains of radiotherapy indications?	C. Haie-Meder	France
	- Discussion		

CS 2 HPV infection & precancers of the vulva

Chair: J. Bornstein - A. Tristram

Auditorium 2

10:00 - 11:30

CS 2-1	- Terminology	J. Bornstein	Israel
CS 2-2	- The distribution of 14 HPV types detected in VIN and VaIN lesions from women 15-26 years of age	S. Garland	Australia
CS 2-3	- Epidemiology of HPV infection	M. Goodman	USA
CS 2-4	- Diagnosis	M. Roy	Canada
CS 2-5	- Treatment - Management	A. Tristram	UK
CS 2-6	- Immunotherapy	E. Van Esch	Netherlands
	- Discussion		

ORAL COMMUNICATIONS - OC

OC 6 Vaccine 3 (New developments)

Chair: P. Bonanni - E. Joura

Auditorium 3

8:15 - 9:45

OC 6-1	- Long-term effectiveness and safety of Gardasil™ in the Nordic countries	S. Kjaer	Denmark
OC 6-2	- Phase II evaluation of a multivalent HPV L1 virus-like particle (VLP) vaccine	A. Luxembourg	USA
OC 6-3	- Immunogenicity and safety of a novel 9-valent HPV L1 virus-like particle vaccine in boys and girls 9-15 years old; comparison to women 16-26 years old	S. Olsson	Sweden
OC 6-4	- Immunogenicity and safety of a novel 9-valent HPV vaccine in girls 9-15 years of age compared to the quadrivalent vaccine	S. Olsson	Sweden
OC 6-5	- Safety and tolerability of a novel 9-valent HPV virus-like particle vaccine	O.E. Iversen	Norway
OC 6-6	- Tolerability and immunogenicity of a multivalent HPV L1 virus-like particle vaccine in 16- to 26-year-old men	X. Castellsagué	Spain
OC 6-7	- End of study efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16-26 year old women	E. Joura	Austria
OC 6-8	- Potential impact of a nine-valent vaccine on human papillomavirus (HPV) related cervical disease in women aged 16-45 years of age, by region	X. Castellsagué	Spain
OC 6-9	- Evaluation of HPV clearance following ProCervix vaccination in HPV 16 / 18 infected women with normal cytology	M. Bouillette-Marussig	France

COLPOSCOPY COURSE

CC Colposcopy course

Coordinators: A. Singer - N. Pisal

Bruselas Room

8:30 - 12:00

SEPARATE REGISTRATION IS REQUIRED FOR THIS COURSE


The colposcopy course is an intensive course conducted by 2 highly experienced colposcopists/oncologists. They will present the most up-to-date knowledge relating to colposcopy practice as well as of the management of the cervix and lower genital tract precancer. There will be lectures as well as a very informal interactive tutorial which will be clinically oriented. Topics will range from the basic (i.e. normal cervix) to advanced (i.e. micro-invasion and glandular disease). A CD (PDF format) of all PowerPoint lectures will be given out.

- 8:00 • Registration
- 8:30 • The normal cervix
- 8:50 • New ideas on CIN and cervical glandular disease and their detection - use of cytology +/- HPV
- 9:40 • Discussion
- 9:50 • The abnormal cervix - the use of colposcopy
(including video presentations)
- 10:40 • Discussion
- 10:50 • Coffee
- 11:00 • Why, who, how to treat CIN/glandular disease
- 11:40 • Interactive case presentation
- 12:00 • Summary and close

Coffee Break

11:30 - 12:00

ORAL COMMUNICATIONS - OC

OC 7 Head & Neck 1			Madrid Room	
Chair: S. Syrjänen - M. Quer - H. Mirghani			8:30 - 10:00	
OC 7-1	- Risk of human papillomavirus-associated head and neck cancer following a diagnosis of cervical intraepithelial neoplasia		M. Svahn	Denmark
OC 7-2	- Human papillomavirus prevalence and genotype profiling in head and neck region: an Italian study		M. Benevolo	Italy
OC 7-3	- The incidence of cervical and head and neck cancer among indigenous people in Australia, Canada, New Zealand, and the United States		S. Moore	Australia
OC 7-4	- Study of HPV and precancerous lesions in the tonsils ("SPLIT"): preliminary results		J.D. Combes	France
OC 7-5	- Prevalence of HPV & P16 ^{INK4A} in multiple primary squamous cell carcinomas of the upper aerodigestive tract		J. Kulasegarah	Ireland
OC 7-6	- Adult onset recurrent respiratory papillomatosis: a retrospective review		N. Blackwell	UK
OC 7-7	- HPV in oral squamous cell carcinoma in India: pathogenesis and clinical implications		N. Husain	India
OC 7-9	- Molecular identification of HPV and its relationship with the presence of premalignant and malignant lesions of the oral cavity in a general hospital, Arequipa, Peru		A. Vasquez	Peru
OC 8 Head & Neck 2			Madrid Room	
Chair: B. Burtneß - L. Licitra			10:00 - 11:30	
OC 8-1	- The role of the stroma in Tumour infiltrating lymphocytes (TILs) in oropharyngeal squamous cell carcinoma (OPSCC)		P. Stern	UK
OC 8-2	- Genomic characterization of a novel human Gammapapillomavirus genotype HPV-199 isolated from nasopharynx		A. Ostrbenk	Slovenia
OC 8-3	- HPV concordance between neck metastases and primary tonsillar cancer		E. Munck-Wikland	Sweden
OC 8-4	- Expression of APM components in oropharyngeal carcinomas in relation to human papillomavirus (HPV) and clinical outcome		T. Ramqvist	Sweden
OC 8-5	- Methylation of HPV16 URR SP1 and E2 binding sites 3 and 4 in matched HPV16 positive primary / metastasis OPSCC pairs		M. Kalteis	Germany
OC 8-6	- Meta-analysis on p16 ^{ink4a} accuracy to identify HPV transformation in oropharyngeal squamous cell carcinomas		M. von Knebel Doeberitz	Germany
OC 8-7	- Determination of human papillomavirus significance in oral premalignant lesions in association with clinical parameters and p16 ^{ink4a} immunohistochemistry		E. Prigge	Germany
OC 8-8	- E6/E7 mRNA in situ hybridization is sensitive and specific to predict patient outcomes in oropharyngeal squamous cell carcinoma (SCC)		J. Zhai	USA
OC 8-9	- Comparative analysis of microRNAs in HPV-positive and negative oropharyngeal cancers highlights different oncogenic mechanisms		H. Mirghani	France

Coffee Break
11:30 - 12:00

MAIN SCIENTIFIC SESSIONS - MSS

MSS 3 - Funding cervical cancer control

Chair: E. Franco

Main Auditorium

14:45 - 16:00

MSS 3-1	- Being victims of our own success: funding decreases for cervical cancer control	E. Franco	Canada
MSS 3-2	- The agenda agencies and charity organizations	D. Wiesch	USA
MSS 3-3	- NIH	S. LaMontagne	USA
MSS 3-4	- PATH		
MSS 3-4	- What do financial cuts in health care systems mean for cervical cancer prevention in Europe?	X. Bosch	Spain
	- Discussion		

Coffee Break

16:00 - 16:30

MSS 4 - Methods of triage of HPV+ women

Chair: C. Meijer, A. Lorincz

Main Auditorium

16:30 - 18:00

MSS 4-1	- Cytology	J. Dillner	Sweden
MSS 4-2	- Host methylation	C. Meijer	Netherlands
MSS 4-3	- Viral methylation and p16 mRNA test	A. Lorincz	UK
MSS 4-4	- p16	N. Wentzensen	USA
MSS 4-5	- Combination strategies	M. Stoler	USA
	- Discussion		

SCIENTIFIC SESSIONS - SS

SS 1 - Immunotherapy of HPV-associated diseases

Chair: M. Stanley - P. Stern

Auditorium 3

14:45 - 16:15

SS 1-1	- Development of immune checkpoint inhibitors for SCCHN therapy	G. Melillo	USA
SS 1-2	- Optimization and development of a therapeutic anti-HPV vaccine in Ear, Nose, Throat (ENT) cancer	C. Badoual	France
SS 1-3	- HPV-specific immunotherapy (VGX-3100) induces potent T-cells responses and regression of cervical intraepithelial neoplasia in a randomized phase IIB study	M. Morrow	USA
SS 1-4	- Protease inhibitor in treatment of CIN	I. Hampson	UK
SS 1-5	- Generation of chimeric P16 ^{INK4A} HPV16 L1 particles for second generation HPV vaccines	F. Faulstich	Germany
SS 1-6	- A phase I/IIa trial targeting p16 ^{INK4a} by peptide vaccination in patients with human papillomavirus-associated cancer	M. Reuschenbach	Germany
SS 1-7	- Human papilloma viral clearance following HPV targeted immunotherapy, tipapkinogen Sovacivec, in patients with high grade CIN	D. Harper	USA
SS 1-8	- Vaxiclav, a new adenylate cyclase-based vaccine vector for multivalent HPV therapeutic vaccination	Y. Misseri	France
	- Discussion		

Coffee Break

16:00 - 16:30

SS 2 - New challenges facing HPV 16 & 18 infection

Chair: X. Bosch

Auditorium 3

16:40 - 18:00

SS 2-1	- HPV 16 & 18 prevalence and burden of associated cancers	G. Clifford	France
SS 2-2	- Assessing cancer risk of HPV 16 & 18 infection	E. Franco	Canada
SS 2-3	- Immune responses, regression and persistence of HPV 16 & 18	A.B. Moscicki	USA
SS 2-4	- Immune responses to HPV therapeutic vaccines	T.C. Wu	USA
SS 2-5	- ProCervix, a new vaccine for HPV 16 & 18 infected women prior to development of high-grade cervical lesions: from Phase I to Phase II.	P. Van Damme	Belgium
SS 2-6	- New paradigms of HPV 16 & 18 associated cancer control, the respective role of prevention, screening and immunotherapy	M. Brisson	Canada
	- Discussion		

CLINICAL SESSIONS - CS
CS 3 - ADC in situ and invasive adenocarcinoma of the cervix: an update **Auditorium 2**

Chair: K. Ault

14:45 - 16:15

CS 3-1	- Current worldwide figures	K. Ault	USA
CS 3-2	- Human papillomavirus types in glandular lesions of the cervix: A meta-analysis of published studies	G. Clifford	France
CS 3-3	- Molecular approaches	J. Doorbar	UK
CS 3-5	- Cervical screening and adenocarcinoma: Impact of cytology based screening and likely impact of HPV testing	P. Sasieni	UK
CS 3-6	- HPV prophylactic vaccine efficacy & impact - Discussion	D. Brown	USA

Coffee Break
16:15 - 16:30
CS 4 - The new face of colposcopy at the age of technical progress **Auditorium 2**

Chair: W. Prendiville - P. Hillemanns

16:30 - 18:00

CS 4-1	- Colposcopy e-training	A. Singer	UK
CS 4-2	- Colposcopic performance & utility today	S. Dexeus	Spain
CS 4-3	- Indications of colposcopy based on HPV screening	W. Huh	USA
CS 4-4	- New biometric diagnostic	W. Prendiville	Ireland
CS 4-5	- The use of an objective test for colposcopic trainees: a ten-year experience - Discussion	M. Roy	Canada

ORAL COMMUNICATIONS - OC
OC 9 - Colposcopy - Management **Auditorium 2**

Chair: E. Siegler - K. Elfgren

18:00 - 19:30

OC 9-1	- Organized primary HPV screening in Sweden. Colposcopic and histopathologic evaluation of HPV++ women aged 56-60	K. Elfgren	Sweden
OC 9-2	- Spectroscopy in cervical cancer screening	H. Kirubamani	India
OC 9-3	- When should endocervical curettage be done?	R. Pretorius	USA
OC 9-4	- EQE of cervical dysplasia: cytology-biopsy evaluation is mandatory for good patient management	C. Vanscheeuwijck	Belgium
OC 9-5	- HPV triage of low grade abnormalities in immunised women - insights from the SHEVa study	R. Bhatia	UK
OC 9-6	- SperAnZA study: preliminary results of HPV vaccination after loop electrosurgical excision procedure for cervical intraepithelial neoplasia	A. Ghelardi	Italy
OC 9-7	- ECO-ROCS (Evaluation of Clinical Outcome after Reduction Of Conization Size), study design	T. Schwarz	Germany
OC 9-8	- Influence of glacial acetic acid on HPV detection - a study of 140 cases of CIN2+	K. Cuschieri	UK
OC 9-9	- Dynamic spectral imaging for post-treatment triage	C. Founta	UK
OC 9-10	- Realtime in vivo microscopic imaging of the cervix using confocal laser endomicroscopy: preliminary observations and feasibility study.	D. Degueudre	Belgium
OC 9-11	- Overtreatment in see-and-treat management of cervical intraepithelial neoplasia; a systematic review and meta-analysis	R. Ebisch	Netherlands

ORAL COMMUNICATIONS - OC

OC 10 - HPV testing 2

Chair: H. Cubie - J.L. Pr  tet

Madrid Room

14:45 - 16:00

OC 10-1	- Technical evaluation of the Xpert [®] HPV Assay in a General Screening Population - an assessment of the clinical performance	J. Cuzick	UK
OC 10-2	- HPV typing for the triage of HPV-positive ASC-US women may reduce costs due to avoidable colposcopies	M. Parisi	USA
OC 10-3	- Detection of high-risk Human Papillomavirus E7 Proteins	I. Koch	Germany
OC 10-4	- Clinical validation of E1-based "HPV Easy DNA Array" genotyping test developed by AID/GenID	A. Pesic	Germany
OC 10-5	- Cross-reactivity to untargeted, low-risk HPV genotypes by cobas, Aptima and HC2	S. Preisler	Denmark
OC 10-6	- Human papillomavirus infection caused by HPV types 52 and 58 and its role in the development of cervical intraepithelial neoplasia	V. Prilepskaya	Russia
OC 10-7	- Does human genomic DNA cause false positive HPV test results	J. Dong	USA
OC 10-8	- Post-conus samples and HPV testing with HC2 and cobas using SurePath: results from two Danish laboratories	D. Fornari	Denmark
OC 10-9	- Virtual screening of human papillomavirus oncoprotein E7	G. Silva	Brazil

Coffee Break

16:00 - 16:30

OC 11- Epidemiology & natural history 2

Chair: P. Sparen - H. Ikenberg

Madrid Room

16:30 - 18:00

OC 11-1	- HPV genotypic distribution in patients with cervical cancer in Thailand	N. Kantathavorn	Thailand
OC 11-2	- HLA-G polymorphism and HPV transmission among heterosexual couples in the HITCH study	K. Louvanto	Canada
OC 11-3	- Do HPV 16 and 18 predict a higher risk of CIN2+ than other high-risk HPV genotypes in triage?	A. Trop��	Norway
OC 11-4	- "Safety in numbers" - HPV genotype-specific vs. pooled high-risk approaches to CIN3+ risk stratification	L. Vaughan	USA
OC 11-5	- Use of Oncotect HPV E6/E7 mRNA as a triage test finds more cancer and high grade dysplasia than HPV 16/18 genotyping or dual staining	P. Karakitsos	Greece
OC 11-6	- Sexually transmitted infections among HIV positive and HPV high-risk patients in North Tongu district, Ghana - an ACCESSING* pilot trial	A. Krings	Germany
OC 11-7	- Persistence of high risk HPV infections among women in the North Tongu district of Ghana - participating in the ACCESSING* trial	P. Dunyo	Ghana
OC 11-8	- Prevalence of risk factors associated with HPV and HIV positivity and cervical cancer among Cameroonian women	R. Catarino	Switzerland
OC 11-9	- The effect of HIV infection on penile high-risk HPV incidence and clearance among MSM	D. Van Santen	Netherlands
OC 11-10	- High-risk types of the human papillomavirus in women diagnosed with a precancerous lesion	K. Iwaniec	Poland
OC 11-11	- Epidemiological study of high-risk HPV in Midi-Pyr��n��es (France) with high-risk HPV RealTime PCR in 2013	M. Bernier	France
OC 11-12	- Human papillomavirus and chlamydia trachomatis co-infection and the severity of cervical neoplasia	S. Rabelo-Santos	Brazil

MAIN SCIENTIFIC SESSIONS - MSS

**MSS 5 Moving from cyto to HPV-based primary screening
- Mutualizing experiences / implementation issues**

Auditorium 3

8:30 - 10:00

Chair: J. Cuzick - G. Ronco

MSS 5-1	- Status of cervical cancer screening in European countries and guidelines	L. von Karsa	France
MSS 5-2	- Introduction of primary HPV screening in organized screening programs	J. Dillner	Sweden
	- Implementation of HPV screening : national vs regional projects (organization, assessment, problems, solutions, results, communications)		
MSS 5-3	- Netherlands	C. Meijer	Netherlands
MSS 5-4	- Italy	G. Ronco	Italy
MSS 5-5	- Germany	P. Hillemanns	Germany
MSS 5-6	- Spain	S. Granado de la Orden	Spain
MSS 5-6a	- Recommendation to introduce HPV-based screening in Belgium	M. Arbyn	Belgium
MSS 5-7	- US (FDA approval)	H. Lawson	USA
	- Discussion		

**MSS 6 - Roadmap 2015:
Management & control of HPV associated diseases
- current knowledge and new horizons - a debate**

Auditorium 3

10:00 - 11:30

Chair: S. Franceschi - J. Monsonogo

	- How HPV knowledge has changed our practice: screening and management of neoplastic lesions		
	• Cervix		
MSS 6-1	- HPV screening in non-vaccinated women	N. Wentzensen	USA
MSS 6-2	- HPV screening in vaccinated women	H. Berkhof	Netherlands
MSS 6-3		K. Canfell	Australia
MSS 6-4	- Role of HPV in the management of abnormal Pap & CIN	M. Einstein	USA
MSS 6-5		M. Arbyn	Belgium
MSS 6-6	• Anus	C. Fairley	Australia
MSS 6-7		M. Bower	UK
MSS 6-8	• Oropharyngeal cancers (OPC)	S. Pai	USA
MSS 6-9		C. Fakhry	USA
	- How HPV knowledge has changed our practice: current and future vaccines		
MSS 6-10	- State of the art of HPV vaccine	J. Brotherton	Australia
MSS 6-11	- Positioning the value of the new HPV vaccine	M. Jit	UK
MSS 6-12	- Utility of cervical cancer screening in the era of multivalent and therapeutic vaccines	P. Gravitt	USA
MSS 6-13	- Impact of prophylactic HPV vaccine in cancers other than cervical cancer	M. Brisson	Canada
	- Discussion		

Coffee Break

11:30 - 12:00

SCIENTIFIC SESSIONS - SS

SS 3 - FIGO session**- Cervical cancer prevention in low-resource countries**

Chair: L. Cabero-Roura

Madrid Room**8:00 – 9:30**

SS 3-1	- Worldwide epidemiology of cervical cancer: prevalence, incidence, mortality. Rates and tendencies.	S. De Sanjosé	Spain
SS 3-2	- Reality of HPV vaccination in under developed countries	S. LaMontagne	USA
SS 3-3	- Cervical cancer in Africa: an epidemic in waiting?	A. Tristram	UK
SS 3-4	- Effect of VIA screening by Primary Health workers: randomized controlled study in Mumbai, India	S. Shastri	India
SS 3-5	- FIGO educational program	X. Bosch	Spain
	- Discussion		

SS 4 - Italian Session (in English) *to the memory of M. Sideri†*Chair: M. Sideri[†] - G. Ronco - M.T. Sandri**Madrid Room****9:30 – 11:30**

SS 4-1	- Overview and update on NTCC trial	G. Ronco	Italy
SS 4-2	- Management of HPV+ women: results of research trials	F. Carozzi	Italy
SS 4-3	- Update on the implementation of HPV primary screening in Italy	P. Giorgio-Rossi	Italy
SS 4-4	- Performance of commercially available HPV tests (from studies to clinical practice)	M.T. Sandri	Italy
SS 4-5	- Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia Romagna region - the Pater study.	S. Costa	Italy
SS 4-6	- Value of RLU in the management of ASC-US pap	M. Origoni	Italy
SS 4-7	- Colposcopy in cytology negative HPV positive women	M. Preti	Italy
SS 4-8	- CINtecplus to triage cytology negative HR positive women	P. Cristoforoni	Italy
SS 4-9	- HPV vaccination in Italy, an update	L. Mariani	Italy
	- Discussion		

Coffee Break**11:30 – 12:00**

CLINICAL SESSIONS - CS
CS 5 - Clinical decision-making for cervical diseases

Chair: A. Kaufmann - J.P. Bogers

Bruselas Room

8:30 - 10:00

CS 5-1	- Pathognomonic signs guiding biopsy and therapy decision	A. Schneider	Germany
CS 5-2	- It is the time to change the consensus about CIN 2-3 LLETZ treatment during the first trimester?	E. Siegler	Israel
CS 5-3	- Managing 21-24 y women with CIN	A.B. Moscicki	USA
CS 5-4	- Role of biomarkers in the management of high grade CIN	N. Wentzensen	USA
CS 5-5	- Non-invasive treatment options for CIN	P. Hillemanns	Germany
CS 5-6	- Risk factors for cervical cancer at colposcopy	R. Pretorius	USA
	- Discussion		

SCIENTIFIC SESSIONS - SS
SS 5 - Spanish Session (in English)

Chair: R. Garrido - F. Martín-Torres

Bruselas Room

10:00 - 11:30

SS 5-1	- Accreditation in colposcopy: The AEPC's program	S. Dexeus	Spain
SS 5-2	- The per-operative sample of HPV as a marker of risk of relapse or second lesion	M. del Pino	Spain
SS 5-3	- Invasive cervical cancer quality control in Spain	M. Castillo	Spain
SS 5-4		R. Ibáñez	Spain
SS 5-5	- Robotic surgery in invasive cervical cancer	M. Barahona	Spain
	- Discussion		

Coffee Break
11:30 - 12:00
SS 6 - Health economical modelling for HPV-induced cervical cancer prevention

Chair: M. Brisson - H. Berkhof

Paris Room

8:30 - 10:15

SS 6-1	- Optimal screening strategies in the era of vaccination in terms of cost-effectiveness – Australia	K. Canfell	Australia
SS 6-2	- Optimal screening strategies in the era of vaccination in terms of cost-effectiveness – The Netherlands	H. Berkhof	Netherlands
SS 6-3	- Optimal number of HPV vaccine doses in terms of cost-effectiveness	M. Brisson	Canada
SS 6-4	- Optimal HPV vaccine in terms of cost-effectiveness (bivalent, quadrivalent, nonavalent)	M. Jit	UK
SS 6-5	- Comparing impact of different vaccination strategies (girls-only, girls & boys, and older women catch-up)	I. Baussano	France
SS 6-6	- Investigating the impact of HPV vaccine on the cost-effectiveness of cervical screening in Denmark	E. Sopina	Denmark
	- Discussion		

SS 7 - Screening strategies at the extremes

Chair: M. Elfström - P. Sasieni

Paris Room

10:15 - 11:30

SS 7-1	- Cervical cancer risk in women <30y & >65y	M. Stoler	USA
SS 7-2	- Screening of women <30y	W. Kinney	USA
SS 7-3	- Screening of older women >65y	P. Sasieni	UK
SS 7-4	- Management of ASCUS/LSIL women under 30	M. Elfström	Sweden
	- Discussion		

Coffee Break
11:30 - 12:00


INTERNATIONAL FORUM ON HPV AND HEAD & NECK CANCER
H&N 1 - HPV driven oropharyngeal cancers (OPC): the global view
Auditorium 2

Chair: X. Castellsagué - A. Chaturvedi

8:15 - 10:00

HN 1-1	- Burden of HPV H&N cancer a new entity? An emerging epidemy?	A. Chaturvedi	USA
HN 1-2	- HPV distribution & epidemiology	X. Castellsagué	Spain
HN 1-3	- Risk factors for HPV head and neck cancers / Natural history - carcinogenesis	M. Gillison	USA
HN 1-4	- Defining risk in HPV-associated head and neck cancer	B. Burtness	USA
HN 1-6	- Role of immunity	M. Pawlita	Germany
	- Discussion		

**MSS 6 - Roadmap 2015:
Management & control of HPV associated diseases-
current knowledge and new horizons - a debate**
Auditorium 3

10:00 - 11:30

- see detailed contents of this session p. 24

Coffee Break
11:30 - 12:00
**H&N 2 - The HPV value for detection, control and management
of oropharyngeal cancers (OPC)**
Auditorium 2

14:45 - 16:30

Chair: C. Fakhry - S. Pai

HN 2-1	- Are HPV head and neck cancers preventable by screening and early detection, and immunization	C. Fakhry	USA
HN 2-2	- Diagnosis & detection	J. Lacau St Guily	France
HN 2-3	- Biomarkers in HPV+ tumors	M. Pawlita	Germany
HN 2-4	- The role of HPV status in the treatment option of HNCC	S. Pai	USA
HN 2-6	- Personalized patient counseling	T. Dalianis	Sweden
	- Discussion		

Coffee Break
16:30 - 17:00
H&N 3 - Decision-making in management of oropharyngeal cancers (OPC)
Auditorium 2

Chair: T. Dalianis - R. Brakenhoff

17:00 - 18:15

	- Treatment		
HN 3-1	• Non surgical	C. Fakhry	USA
HN 3-2	• Surgical - robotic surgery	C. Fakhry	USA
HN 3-3	- Radiosensitivity of HPV positive tumors	J. Lacau St Guily	France
		H. Mirghani	France
HN 3-4	- Prognosis & impact of HPV status in recurrent/metastatic OPC	L. Licitra	Italy
HN 3-5	- Ongoing trials	M. Gillison	USA
HN 3-6	- Decision-making in head and neck cancers	S. Pai	USA
	- Discussion		

H&N 4 - H&N controversies and key questions
Auditorium 2

Chair: A. Chaturvedi - J. Lacau St Guily - F. Esteban - B. Burtness - M. Gillison

18:15 - 19:15

- Debate

MAIN SCIENTIFIC SESSIONS - MSS
MSS 7 - New insights in cervical cancer control

Chair: J. Paavonen - S. Garland

Auditorium 3

14:45 - 16:30

MSS 7-1	- Community randomized HPV vaccination trial of the best vaccination strategy	M. Lehtinen	Finland
MSS 7-2	- The efficacy rates against CIN3 obtained by the quadrivalent and the bivalent vaccine Phase III trials were not identical-Why?	J. Paavonen	Finland
MSS 7-3	- Screening approaches for vaccinated population: Compass trial	K. Canfell	Australia
MSS 7-4	- How to integrate HPV vaccination programs and organized screening programs	P. Nieminen	Finland
MSS 7-5	- Addressing an unmet medical need using a 9-valent virus-like particle (VLP)-based HPV vaccine	A. Saah	USA
	- Discussion		

Coffee Break

16:30 - 17:00

MSS 8 - Potential impact of the quadrivalent, bivalent and nonavalent HPV vaccines, and alternative HPV vaccination strategies

Chair: M. Brisson - M. Jit

Auditorium 3

17:00 - 18:15

MSS 8-1	- Impact of cross-protection on overall vaccination effectiveness against HPV-related diseases	H. Berkhof	Netherlands
MSS 8-2	- Alternative dosing schedules, WHO perspective	A.M.Henao-Restrepo	Switzerland
MSS 8-3	- Effectiveness and cost-effectiveness of the candidate nonavalent vaccine	M. Brisson	Canada
MSS 8-4	- Age-specific sexual activity patterns and HPV infection control	I. Baussano	France
MSS 8-5	- Effectiveness and cost-effectiveness of vaccinating Men-who-Have-Sex-with-Men	M. Jit	UK
MSS 8-6	- Impact of the nonavalent vaccine on cervical screening paradigms	K. Canfell	Australia
	- Discussion		

CLINICAL SESSIONS - CS
CS 6 - HPV infection: the state of the art

Chair: M. Goodman - E. Franco

Paris Room

14:45 - 16:30

CS 6-1	- Men and women epidemiology - genital vs anal & oral	A. Giuliano	USA
CS 6-2	- Immunological factors which may be common or different at oral, anal or genital sites of infection	P. Stern	UK
CS 6-3	- HPV infection in children	S. Syrjänen	Finland
CS 6-4	- Current knowledge on transmission	M. Goodman	USA
CS 6-5	- The environment of HPV	A.B.Moscicki	USA
	- Discussion		

Coffee Break

16:30 - 17:00

CS 7 - Anogenital HPV infection in men

Chair: A. Giuliano - J. Palefsky

Paris Room

17:00 - 18:15

CS 7-1	- Can men having sex with men perform self or partner assisted digital anal exams? A study protocol	A. Nyitray	USA
CS 7-2	- The utility of HR anoscopy in the management of AIN	M. Bower	UK
CS 7-3	- Epidemiology of anal HPV infection, transmission and natural history	A. Nyitray	USA
CS 7-4	- Management of genital warts: updated guidelines	M. Steben	Canada
CS 7-5	- Performance of anal Aptima HPV testing alone and with anal cytology for detection of anal high-grade squamous intraepithelial lesions	J. Palefsky	USA
CS 7-6	- Genital high-risk human papillomavirus (HPV) infection among men in Denmark: prevalence and risk factors	J. Hebnæs	Denmark
	- Discussion		

SCIENTIFIC SESSIONS - SS

SS 8 - Cancers associated with HPV: the current picture

Chair: S. De Sanjosé - K. Syrjänen

Madrid Room

14:45 - 16:45

SS 8-1	- Introduction: overall picture and gaps	S. De Sanjosé	Spain
SS 8-2	- Methodological issues	E. Franco	Canada
SS 8-3	- Cervix - vagina - vulva and penis	S. De Sanjosé	Spain
SS 8-4	- Anus	C. Fairley	Australia
SS 8-6	- HPV persistence/p53 overexpression and treatment outcome post-endoscopic ablation of Barrett's esophagus	S. Rajendra	Australia
SS 8-7	- Skin	S. Smola	Germany
SS 8-8	- Other cancers	K. Syrjänen	Finland
SS 8-9	- Ecology of high-risk human papillomavirus (HR-HPV) infections in heterosexual men (MSW), studied using expressed prostate secretions (EPS) versus anogenital samples	C. Eklund	Sweden
	- Discussion		

Coffee Break

16:45 - 17:00

SS 9 - Self-sampling at the edge of becoming routines

Chair: M. Arbyn - N. Wentzensen

Madrid Room

17:00 - 18:15

SS 9-1	- Accuracy of HPV testing using self-collected vaginal specimen: an updated meta-analysis	M. Arbyn	Belgium
SS 9-2	- Coverage increase by offering self-sampling kits to non-participating women	F. Verdoodt	Belgium
SS 9-3	- How to triage women being hrHPV-positive on a self-sample	V. Verhoef	Netherlands
SS 9-4	- HPV detection from urine- an alternative for self-sampling	N. Wentzensen	USA
SS 9-5	- Can self-sampling become the main strategy in an HPV-based cervical cancer screening programme?	D. Heideman	Netherlands
	- Discussion		

SCIENTIFIC SESSIONS - SS

SS 10 - Recent advances on HPV latency

Chair: P. Gravitt

Bruselas Room

14:45 - 16:30

SS 10-1	- ROPV models of latency and immunosuppression	J. Doorbar	UK
SS 10-2	- Canine models of latency and role of vaccine in suppressing reactivation	M. Stanley	UK
SS 10-3	- HPV latency in RRP: immune control and clinical implications	B. Steinberg	USA
SS 10-4	- Evidence for latency in HIV-infected women	P. Gravitt	USA
SS 10-5	- HPV load fluctuations and duration of detectable episodes vs. duration of infection in adolescents	D. Brown	USA
SS 10-6	- HPV latency in menopausal women	A. Rositch	USA
	- Discussion		

Coffee Break

16:30 - 17:00

SS 11 - New insights in immunology

Chair: S. van der Burg - A.B. Moscicki

Bruselas Room

17:00 - 18:15

SS 11-1	- HPV immunology, genital vs oral	S. van der Burg	Netherlands
SS 11-2	- Immunology of regression vs persistence	A.B. Moscicki	USA
SS 11-3	- Immune responses to HPV prophylactic vaccines	M. Einstein	USA
SS 11-4	- Novel approaches for therapeutic vaccination of HPV-associated neoplasia	M. Reuschenbach	Germany
SS 11-5	- The role of natural immune control in the effectiveness of non-immune treatment	A. Kaufmann	Germany
	- Discussion		

SS 12 - The biology of HPV: what's new?

Chair: J. Doorbar - S. Smola

Bruselas Room

18:15 - 19:30

SS 12-1	- HPV epithelial tropisms and the site-specific development of neoplasia	J. Doorbar	UK
SS 12-2	- Epithelial target cell and the development of cervical disease; current thinking & observations	O. Reich	Austria
SS 12-4	- HR + LR protein function in Alpha HPV infections and carcinogenesis	L. Banks	Italy
SS 12-5	- Viral gene action during HPV infection - immune evasion strategies + persistence	S. Smola	Germany
	- Discussion		

MAIN SCIENTIFIC SESSIONS - MSS
MSS9 - HPV vaccines: unexpected findings

Chair: E. Joura - M. Safaeian

Auditorium 3

8:30 - 10:00

MSS 9-1	- L2-based HPV second generation vaccines (RG1-VLP)	C. Schellenbacher	Austria
MSS 9-2	- Attribution of vaccine types in mixed infection	E. Joura	Austria
MSS 9-3	- HPV vaccination in the immunocompromised	A.B. Moscicki	USA
MSS 9-4	- Utility of fewer doses - effectiveness	M. Safaeian	USA
MSS 9-5	- Impact of HPV 16-18 vaccination on genital warts	D. Mesher	UK
MSS 9-6	- Cross-neutralising antibodies in the cross-protection against 16/18 by bivalent & quadrivalent vaccines	J. Paavonen	Finland
	- Discussion		

MSS 10 - Novel approaches of HPV and non HPV-based cervical cancer screening

Chair: P. Snijders - K. Cuschieri

Auditorium 3

10:00 - 11:30

MSS10-1	- Biomarker tests	M. von Knebel Doeberitz	Germany
MSS 10-2	- Methylation	P. Snijders	Netherlands
MSS 10-3	- Genotyping	J. Cuzick	UK
MSS 10-4	- mRNA	K. Cuschieri	UK
MSS 10-5	- Self-sampling	D. Heideman	Netherlands
MSS 10-6	- Novel approaches of HPV and non-HPV-based cervical cancer screening in developing countries	A. Lorincz	UK
	- Discussion		

SCIENTIFIC SESSIONS - SS
SS 13 - Basic molecular techniques and quality control of HPV testing

Chair: M. Poljak - F. Carozzi

Auditorium 3

11:30 - 13:00

SS 13-1	- Quality control of HPV testing in cervical cancer screening: from the patient sample to the communication of the results	H. Cubie	UK
SS 13-2	- Commercially available HPV tests, global overview and future challenges	M. Poljak	Slovenia
SS 13-3	- Cervical cancer screening of the vaccinated cohorts	M. Arbyn	Belgium
SS 13-4	- Clinically oriented external quality assurance programmes for HPV diagnostic tests: urgent need	F. Carozzi	Italy
SS 13-5	- Internal quality control requirements and external quality assurance programs for commercial and in-house HPV genotyping tests: current status	C. Eklund	Sweden
SS 13-6	- Novel HPV types beyond HPV-150: an overview	J. Dillner	Sweden
SS 13-7	- Global genomic diversity of HPV 6 and 11	M. Jelen	Slovenia
	- Discussion		

ORAL COMMUNICATIONS - OC
OC 12 - Screening

Chair: B. Andrae - E. Lynge

Auditorium 2

8:15 - 10:00

OC 12-1	- Liquid based cytology (ThinPrep) and computer assistance compared to conventional cytology; seven years' experience in 310 203 cases	A. Xhaja	Germany
OC 12-2	- Normal smears and specimens with benign cellular changes: are they really equivalent? Data from 95 934 cases	J.J. Baldauf	France
OC 12-3	- Benefit of cervical screening in young women - a matter of adherence to the recommended screening interval	P. Sparen	Sweden
OC 12-4	- Age at first smear and cervical cancer risk: recent UK incidence and mortality trends	C. Gilham	UK
OC 12-5	- Cervical cancer incidence after a negative smear: comparing SurePath and ThinPrep with conventional cytology	K. Rozemeijer	Netherlands
OC 12-6	- Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage rate in Denmark	E. Lynge	Denmark
OC 12-7	- Evaluation of three strategies to increase cervical cancer screening coverage among women age 30 to 70 years old. CRICERVA	S. De Sanjosé	Spain
OC 12-8	- Impact of overscreening, data from a French organized programme	M. Fender	France
OC 12-9	- Cervical cancer prevented by screening: long-term incidence trends by morphology and region in Norway	S. Lönnberg	Norway
OC 12-10	- Estimating the contribution from unspecified uterine cancer to cervical cancer mortality	B. Andrae	Sweden
OC 12-11	- The impact of cervical cancer screening on preterm birth: a decision analysis	S. Naber	Netherlands
OC 12-12	- Effect of HR-HPV immunisation on the performance of cervical cytology	T. Palmer	UK
OC 12-13	- Characteristics of GPs who do not engage in cervical cancer screening in France	L. Poncet	France

ORAL COMMUNICATIONS - OC

OC 13 - HPV Screening

Chair: M. Rebolj - F. Carozzi

Auditorium 2

10:00 - 12:00

OC 13-1	- Misleading round 1 results in HPV screening studies due to high rate of previously undiagnosed CIN ₃	J. Peto	UK
OC 13-2	- Complete age specific round 1 results from the Canadian population-based screening trial: HPV focal	G. Ogilvie	Canada
OC 13-3	- Human papillomavirus assays and cytology in primary cervical screening of women below age 30 years	J. Bonde	Denmark
OC 13-4	- Referral population studies in evaluation of HPV assays for primary screening	M. Rebolj	Denmark
OC 13-5	- The long-term prognostic value of HPV testing and Pap cytology to detect cervical neoplasia in the Canadian cervical cancer screening trial (CCCST)	S. Isidean	Canada
OC 13-6	- Evaluating the potential introduction of primary HPV DNA screening in England	I. Bains	UK
OC 13-7	- HPV testing with cytological triage versus conventional cytology in an organized cervical cancer screening program	O. Veijalainen	Finland
OC 13-8	- Performance of HPV DNA testing with individual HPV 16/18 genotyping for primary cervical cancer screening and triage, compared to cytology	T. Agorastos	Greece
OC 13-9	- Clinical characteristics of samples where cobas, HC2, Aptima, and CLART HPV assays return different test results	C. Rygaard	Denmark
OC 13-10	- The added value of rescreening cytology normal samples with positive HPV mRNA test for the detection of CIN ₂₊ in primary screening	F. Skjeldestad	Norway
OC 13-11	- Exploring the value of a rapid, on demand test for HPV as part of cervical cancer screening pathways	E. Adams	UK
OC 13-12	- Start-HPV French pilot primary screening program for cervical cancer: participation results	V. Dalstein	France
OC 13-13	- Introducing careHPV into a public sector screening program in El Salvador	M. Cremer	USA
OC 13-14	- Randomized implementation of HPV-test in primary screening in the Norwegian cervical cancer screening program	T. Andreassen	Norway
OC 13-15	- Cervical cancer screening program based on cytology and HPV test: positive predictive value	S. Tamames	Spain
OC 13-16	- HPV screening in the Netherlands: determination of HPV prevalence using 3 different automated HPV systems	A. Van den Brule	Netherlands

OC 14 - Self-sampling

Chair: D. Heideman - J. Bonde

Auditorium 2

12:00 - 13:15

OC 14-1	- HPV prevalence findings in the Danish HPV self-sampling implementation compared to routine screening	H. Pedersen	Denmark
OC 14-2	- Comparative evaluation of two vaginal self-sampling devices for the detection of human papillomavirus infections	M. Jentschke	Germany
OC 14-3	- Good agreement of HPV detection between self-collected dry samples and physician-collected specimens in China	K. Chen	Germany
OC 14-4	- HPV-based self-sampling implementation with an opt-in strategy to improve cervical screening coverage	J. Lam	Denmark
OC 14-5	- Clinical validation of self HPV testing in routine screening in Scotland	G. Stanczuk	UK
OC 14-6	- ACCESSING*: screening by self-sampling and low cost Arbor Vita E6 oncoprotein test can detect dysplasia in high risk women	K. Effah	Ghana
OC 14-7	- Feasibility of self-collection and dry specimen storage for HPV mRNA testing to detect cervical lesions in high risk women	G. Manguro	Kenya
OC 14-8	- Self-collected vs. provider-collected sampling for HPV DNA testing in a population-based cervical cancer prevention program in rural El Salvador	J.C. Felix	USA

SCIENTIFIC SESSIONS - SS
SS 14 - CoheaHr

Chair: C. Meijer - M. Elfström

Madrid Room
8:00 - 10:00

SS 14-1	- Overview of CoheaHr. Self-sampling for primary HPV screening	H. Berkhof	Netherlands
SS 14-2	- Comparative effectiveness research in optimization of cervical cancer control	J. Dillner	Sweden
SS 14-3	- HPV clearance rates: impact on cervical cancer control strategies	G. Ronco	Italy
SS 14-4	- HPV transmission modelling in optimizing preventive strategies	I. Baussano	France
SS 14-5	- Vaccination of mid-adult women	X. Bosch	Spain
SS 14-6	- Efficacy of HPV vaccines	M. Arbyn	Belgium
SS 14-7	- Effect of vaccination strategies on screening	N. Veldhuijzen	Netherlands
SS 14-8	- Integration of vaccination and screening	M. Lehtinen	Finland
	- Discussion		

SS 15 - Prevention of cervical cancer in Central and Eastern Europe and Central Asia

Chair: M. Poljak

Madrid Room
10:00 -11:30

SS 15-1	- Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia	F. Bray	France
SS 15-2	- Cervical cancer screening practices and current status of vaccination implementation in the Russian Federation	S. Rogovskaya	Russia
SS 15-3	- Cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe	K. Seme	Slovenia
SS 15-4	- Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia	H. Berkhof	Netherlands
SS 15-5	- Recommendations for cervical cancer prevention in Central and Eastern Europe and Central Asia	M. Poljak	Slovenia
	- Discussion		

SS 16 - HPV infection, cervical cancer prevention in low income countries

Chair: R. Sankaranarayanan

Madrid Room
11:30 -13:00

SS 16-1	- Cervical cancer prevention initiatives in China: Care HPV	Y.L. Qiao	China
SS 16-2	- Updated results from the Indian study of less than 3 doses of HPV vaccination	R. Sankaranarayanan	France
SS 16-3	- Cervical cancer prevention in HIV infected women	J. Smith	USA
SS 16-4	- Infection with <i>C. trachomatis</i> increases high-risk human papillomavirus infection duration among female sex workers in Kenya	N. Vielot	USA
SS 16-5	- Developing a sustainable programme of cervical screening by 'see and treat' in rural Malawi	H. Cubie	UK
SS 16-6	- Risk factors for HIV positivity according to HPV status among Tanzanian women	M. Faber	Denmark
	- Discussion		

ORAL COMMUNICATIONS - OC

OC 15 - Anal neoplasia

Chair: J. Palefsky - A. Nyitray

Bruselas Room

8:30 - 10:00

OC 15-1	- Diagnostic value of anal cytology, HPV testing and high resolution anoscopy (HRA) in screening for anal intraepithelial neoplasia (AIN) in HIV positive individuals	D. Grover	UK
OC 15-2	- Persistence, incidence, and clearance of anal HPV among HIV-negative men having sex with men and men having sex with women and men	A. Nyitray	USA
OC 15-3	- The effect of HIV infection on anal high-risk HPV incidence and clearance among MSM	S. Mooij	Netherlands
OC 15-4	- Correlates of higher burden of anal high-grade squamous intraepithelial lesions (HSIL) in the study for the prevention of anal cancer (SPANC)	D. Templeton	Australia
OC 15-5	- Stratifying risk of development of anal cancer - a proposed clinical algorithm	M. Poynten	Australia
OC 15-6	- Anal cancer screening in HIV positive Czech MSM	J. Kaspirkova	Czech Republic

OC 16 - Vulvar, vaginal & other neoplasia

Chair: A. Tristram - F. Borruto

Bruselas Room

10:00 - 11:30

OC 16-1	- Sexual activity and function in patients with preinvasive and invasive vulvar lesions after completed treatment	D. Grimm	Germany
OC 16-2	- Role of vulvar cytology vs colposcopy in women with chronic vulvovaginal complaints and future role of HPV PCR as a primary screening modality	S. Wadhwa	India
OC 16-3	- Randomized trial of treatment and follow-up of vaginal intraepithelial neoplasia	K. Tainio	Finland
OC 16-4	- Risk factors and outcomes of women with vaginal intraepithelial neoplasia grade 2 and 3 (VaIN 2/3) – an eleven-year experience	M.J.Seet	Singapore
OC 16-5	- Trends in mortality of human papillomavirus-related cancers in 1975-2012, from the Kanagawa cancer registry, Japan	Y. Motoki	Japan
OC 16-6	- HLA class II antigen expression in cervical intraepithelial neoplasia and invasive cancer	M. Sauer	Germany

OC 17 - Molecular markers biology & immunology

Chair: M. von Knebel Doeberitz - M. Safaeian

Bruselas Room

11:30 - 13:00

OC 17-1	- Methylation of human papillomavirus 16 L1 gene in cervical intraepithelial neoplasia and cancer	A. Gutierrez	Germany
OC 17-2	- Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3	E. Schuurin	Netherlands
OC 17-3	- HPV OncoTect Quantitative E6, E7 mRNA as a Single Test Alternative to HPV 16, 18 and PAP Reflex Following Primary HPV DNA Screening	D. King	USA
OC 17-4	- Genome-wide methylome analysis discovers novel methylation markers for both cervical adenocarcinomas and squamous cell carcinomas	G. Wisman	Netherlands
OC 17-5	- Comparison of manual processing for p16/ki-67 dual stain	H. Ikenberg	Germany
OC 17-6	- Established and novel protein biomarkers for early detection of cervical cancer cells	P. Jansen-Dürr	Austria
OC 17-7	- Epigenetic control of human papillomavirus late gene expression	M. von Knebel Doeberitz	Germany
OC 17-8	- Identification of novel key modules regulating cell cycle and apoptosis in cervical carcinoma	K. Pappa	Greece
OC 17-9	- The epigenetic drug 5-AZA-2'-deoxycytidine downregulates the viral oncogenes E6 & E7 AND reduces proliferation in HPV associated cancers	M. Stich	Germany
OC 17-10	- Cofilin-1 and Cathepsin-D are putative early cervical cancer biomarkers	N. Anagnou	Greece
OC 17-11	- Secretome map study of normal and malignant cervical cell lines	G. Kontostathi	Greece

POSTERS

P 1		Epidemiology	
P 1-1	- Prevalence of HPV in a Portuguese population centre Lisbon	D. Cochicho	Portugal
P 1-2	- Prevalence of intraepithelial lesions of the lower genital tract in patients <24 years	S. Tatti	Argentina
P 1-3	- Detection of beta and gamma human papillomaviruses in anal swabs of HIV-infected and uninfected men who have sex with men	M.G. Dona	Italy
P 1-4	- Mother-to-infant transmission of high-risk human papillomavirus	F. Borruto	Monaco
P 1-5	- Pattern of high-risk HPV viral load after quadrivalent HPV vaccination in patients treated by conization	J. Paek	South Korea
P 1-6	- Genotype distribution of human papillomavirus in men from Salvador, Bahia, Brazil	K. Serravalle	Brazil
P 1-7	- HPV types present in external genital warts in the Argentinean population	L. Fleider	Argentina
P 1-8	- Distribution of cervical lesions in São Tomé e Príncipe Democratic Republic - a middle Africa Country	L. Gonçalves	Portugal
P 1-9	- Performance of cobas 4800 HPV testing and genotype - specific distribution in opportunistic cervical cancer screening	M.L. Mateos	Spain
P 1-10	- Natural history of cervical HPV infections in different groups of high risk women enrolled in the VALHIDATE study	G. Orlando	Italy
P 1-11	- HPV genotypes in intraanal samples of immunocompetent women and clinical and liquid-based cytology findings	J. Eleutério	Brazil
P 1-12	- High prevalence of human papillomavirus (HPV) in vulvar and vaginal carcinomas from Brazil	V. Saddi	Brazil
P 1-13	- High grade squamous intraepithelial lesion in an adolescent: a case study	V. Andrade	Brazil
P 1-14	- Is there a clinical profile for patients with persistent HPV infection after conization ?	M. Olalla Jimenez	Spain
P 1-15	- Prevalence of chlamydia trachomatis infection on a cohort of selected asymptomatic young women in Milan, Italy	S. Bianchi	Italy
P 1-16	- Sexual behavior and HPV infection in adolescents and young women	A. Ribeiro	Brazil
P 1-17	- Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in Martinique (French West Indies)	R. Cesaire	France
P 1-18	- Human papillomavirus genotypes in São Tomé e Príncipe Democratic Republic - a middle Africa Country	R. Nobre	Portugal
P 1-19	- Role of quantitative viral load and physical status of Human papillomavirus (HPV) type 16 for prognosis of effectiveness of cervical cancer treatment	L. Mkrtychyan	Russia

POSTERS

P 2 Vaccine

P 2-1	- Evaluating the early impact of quadrivalent HPV vaccine introduction on genital warts in Belgium	G. Dominiak-Felden	Belgium
P 2-2	- Assessing type-replacement following HPV vaccination	J. Palmroth	Finland
P 2-3	- Cancer registry follow-up of HPV vaccination trial cohorts and unvaccinated cohorts	J. Paavonen	Finland
P 2-4	- Cost-effectiveness of HPV vaccination in developing countries	K. Natunen	Finland
P 2-5	- Projecting the potential public health impact of a 9-valent HPV vaccine in the Czech Republic	M. Pillsbury	USA
P 2-6	- Baseline characteristics of a randomized screening trial of HPV vaccinated women	P. Nieminen	Finland
P 2-7	- Prevalence of HPV DNA in adolescent men vaccinated with the HPV 16/18 vaccine	T. Petäjä	Finland
P 2-8	- Prevalence of genital HPV infection in women aged 18-29, in the post vaccination period, Quebec, Canada	P. Goggin	Canada
P 2-9	- Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France	D. Riethmüller	France
P 2-10	- Projecting the potential public health impact of a vaccination programme with a nine-valent HPV vaccine in Norway	M. Adam	France
P 2-11	- Projecting the potential public health impact of a 9-valent HPV vaccine in Hungary	M. Pillsbury	USA
P 2-12	- Correlation between local and systemic IgG and IgA responses against HPV-16/18 VLP during HPV vaccination	P. Giraldo	Brazil
P 2-13	- Provider insight into strategies to increase HPV vaccine uptake: a multi-site study	J.Y. Islam	USA
P 2-14	- Performance of a trial organization in the conduct of a large cluster-randomized trial	M. Lehtinen	Finland

POSTERS
P 3 HPV testing

P 3-1	- Modified pre-processing method for SurePath liquid-based cytology: assessing impact on the performance of the realtime high-risk HPV assay	A. Sargent	UK
P 3-2	- Comparison of HPV direct flow chip system with Hybrid Capture II method for detection of human papillomavirus in women with previous abnormal Pap smears	A. Olmo	Spain
P 3-3	- Primary HPV test in cervical cancer screening in Latin (Italy)	C. Della Rocca	Italy
P 3-4	- Comparison of Xpert® HPV assay versus Aptima® HPV assay	D. Henley	USA
P 3-5	- Comparison between direct sequencing and direct flow chip for human papillomavirus (HPV) genotyping, in formalin-fixed paraffin-embedded (FFPE) biopsies	J.A. Garcia	Spain
P 3-6	- Comparison between a realtime-PCR, DNA-based HPV test and the HPV APTIMA	G. Helenius	Sweden
P 3-7	- Improving laboratory efficiency by automation of pre-analytic processing of ThinPrep specimens for realtime high risk HPV testing	S. Venturoli	Italy
P 3-8	- Cervical cytology specimen stability in SurePath preservative and analytical sensitivity for HPV testing with the cobas® and Hybrid Capture 2® tests	K. Tardif	USA
P 3-9	- Quality assurance of HPV testing within the NHSCSP	L. Hesketh	UK
P 3-10	- HPV detection and typing by molecular diagnostic Microarray	M. Cavalari	Germany
P 3-11	- Triple negative breast cancers (TNBC) and markers of HPV involvement	M. Bews-Hair	UK
P 3-12	- Statistical study of HPV genotypes in Barbastro area	M.D.Comes García	Spain
P 3-13	- Comparison of two HPV genotyping methods: HPV direct flow chip and GenoFlow HPV array kit	L. Marques	Spain
P 3-14	- Comparison of FLOQSwabs for cervico-vaginal self-collection to gynecologist collected cervical specimens for the detection of HPV-DNA with Anyplex™II HPV28 assay.	S. Castriciano	Italy
P 3-15	- Quality of life of persistently HPV DNA screen-positive women	T. Eriksson	Finland
P 3-16	- Organization of in-depth examination of the Rostov region female population with the aim of cervical disease detection at the facilities of regional clinical diagnostic center	T. Kholodnaya	Russia
P 3-17	- Biochemical investigations of human papillomavirus infected cervical fluids	Y.H. Kim	South Korea
P 3-18	- Persistence of HPV after conization in a referral hospital in Spain	S. Pérez Rodríguez	Spain
P 3-19	- Comparison between HPV OncoTect and nucliSENS EasyQ assay and its potential role in detecting preneoplastic lesions of the cervix	M. Rongioletti	Italy
P 3-20	- The 16, 18 and 45 HPV infection triage in primary hr-HPV test screening program	C. Di Cristofano	Italy
P 3-21	- Clinical validation of the Anyplex II HPV HR detection for the cervical cancer screening in Korea	S.Y. Kim	South Korea
P 3-22	- Improved methods for human papillomavirus detection and characterization without DNA extraction, using a low density micro array technology, CLART® HPV=4	A. Moraga	Spain
P 3-23	- Comparative analysis of cervical cytology and HPV genotyping by 3 different methods in routine diagnostic setting	E. Padalko	Belgium
P 3-24	- Detection of high-risk HPV (hrHPV) genotypes among the Ecuadorian female population with cobas 4800	H. Zambrano	Ecuador
P 3-25	- GeneXpert® HPV assay evaluation in a LSIL setting	C. Sousa	Portugal

POSTERS

P 4 Molecular markers

P 4-1	- Using acute oncology to drive translational science: identifying potential biomarkers to overcome resistance mechanisms of ovarian cancer	J. Kwok	UK
P 4-2	- Type-specific HPV prevalence in women at high risk of invasive cervical disease: data from the baseline of the Italian VALHIDATE study	E. Tanzi	Italy
P 4-3	- Structural and level oncogenicity correlation between human papillomavirus variants E7	E. Tamarozzi	Brazil
P 4-4	- Overexpression of HPV E6/E7 mRNA: a marker for high-grade squamous intraepithelial lesions progression in Puerto Rican population	K. Melendez	Puerto Rico
P 4-5	- Human papillomavirus E6/E7 mRNA as cervical cancer biomarker	M. Basaras	Spain
P 4-6	- mRNA expression of genes KI67, p16, PGR and BCL2 as markers of increased risk of neoplastic transformation with HPV-associated cervical disease	N. Nazarova	Russia
P 4-7	- Proteomic map study of cervical cancer cell lines	V. Lygirou	Greece

P 5 Screening

P 5-1	- Optimal age for the onset of HPV-based primary cervical cancer screening using the cobas [®] HPV test	K. Chatzistamatiou	Greece
P 5-2	- High risk human papillomavirus population screening and intratypic variants detection in northern Spain	R. Cisterna	Spain
P 5-3	- In silico modeling of human papillomavirus type 16 (HPV16) E6 protein	S. Giuliatti	Brazil
P 5-4	- Restriction of cervical cancer in Latvia: opportunities and challenges	I. Jermakova	Latvia
P 5-5	- Cancer screening in low resource setting	H. Kirubamani	India
P 5-6	- Modeling to improve: coverage and participation rate in an organized cervical cancer screening program	S. Tamames	Spain
P 5-7	- Cervical cancer screening: Albania's dilemmas and preliminary results	L. Shundi	Albania
P 5-8	- Cost-effectiveness of HPV DNA versus HPV mRNA testing under current United States guidelines for cervical cancer screening	J. Smith	USA
P 5-9	- Secondary prevention of cervix cancer in the Madrid region: a proposal for a change	J. Hernandez-Aguado	Spain
P 5-10	- p16/Ki-67 dual-stain cytology in cervical cancer screening: future is now? Our own experience in a first level hospital	A. Zambruno	Spain

P 6 Diagnosis methods

P 6-1	- Raman microspectroscopy for cytological screening of cervical cancer	I. Ramos	Ireland
P 6-2	- Application of 2-tiered nomenclature for cervical intraepithelial neoplasia in clinic	Y. Zhao	China
P 6-3	- Anoscopy could be beneficial for women with external genital condyloma ?	O. Aynaud	France

POSTERS
P 7 Colposcopy & management

P 7-1	- Colposcopic findings in cervical dysplasia	I. Baasland	Norway
P 7-2	- Investigation of the biochemical signature associated with HPV E7 oncogene expression using Raman spectroscopy	P. Kearney	Ireland
P 7-3	- A single colposcopist can improve detection of invasive cervical cancer in women with negative cytology in Brazil	L. Resende	Brazil
P 7-4	- Dynamic spectral imaging for triage of low grades	R. Naik	UK
P 7-5	- New technology for cervical cancer screening and HPV testing based on Raman spectroscopy	D. Traynor	Ireland
P 7-6	- Tumor-cervical tuberculosis: report of a case	O. Gassama	Senegal
P 7-7	- Diagnostic and therapeutic management of cervical intraepithelial neoplasia grade 2 (CIN2)	P. Garutti	Italy

P 8 Cervical cancer

P 8-1	- Differences in relapsed pattern between radical hysterectomy and radical trachelectomy in the management of early cervical cancer	S.Y. Choi	South Korea
P 8-2	- Cervical cancer staging: an imaging review	L. McIntosh	USA
P 8-3	- Reduced glycosylation levels of serum anti-HPV type 16 E7 immunoglobulin are critical markers indicating cervical carcinogenesis	S.C. Kim	South Korea
P 8-4	- Comparative study of Robotic radical hysterectomy versus laparoscopic radical hysterectomy in cervical cancer	S.H. Kwon	South Korea

P 9 Head & Neck

P 9-1	- Prevalence and expression of human papillomavirus in Greek patients with head and neck squamous cell carcinomas	E. Panotopoulou	Greece
P 9-2	- High-risk HPV-associated hypopharyngeal cancers occur frequently in the pyriform sinus	J.O. Park	Japan
P 9-3	- ¹⁸ F-FDG PET/CT and high-risk HPV in hypopharyngeal squamous carcinoma	S.Y. Kim	Japan
P 9-4	- The burden of head & neck cancers in Iași, Romania	R. Ursu	Romania
P 9-5	- Human papillomavirus detection in oral mucosa can suggest genital infection?	M. Leal Passos	Brazil

POSTERS

P 10 Sexually transmitted diseases

P 10-1	- Longterm prediction accuracy of HPV testing for cervical cancer prediction	H.C. Chen	Taiwan
P 10-2	- Uncaria tomentosa and topical use in genital herpes in vulva: case report	E. Fedrizzi	Brazil
P 10-3	- Placentitis cryptococcal pregnant patient HIV + associated with opportunistic comorbidities: case report	C. Silva	Brazil

P 11 Treatment & management

P 11-1	- Early decrease in anogenital warts treatment when introducing a broad quadrivalent HPV vaccination program: a study from 3 Nordic countries	D. Olsen	Norway
P 11-2	- Dynamin II as potential therapeutic target in cervical carcinoma	J.W. Lee	South Korea
P 11-3	- α 2B-interferon and tilorone in the treatment of CIN with lesions of the vaginal fornix and walls	N. Lygyrda	Ukraine
P 11-4	- Histological correlations in cases of ASCUS or ASC-H cytology and HPV cervical infection	G. Dinca	Romania
P 11-5	- Frequency and characteristics of affected edges after conization	I. Jurado Navarrete	Spain
P 11-6	- Successful treatment of a giant condyloma acuminatum of vulva	S. Mendes	Portugal

P 12 Health education

P 12-1	- The affordable care act: the women who will be left behind	L. Ramondetta	USA
--------	--------------------------------------------------------------	---------------	-----

P 13

P 13-1	- Development of point of care automated detection platform for cervical cancer and HPV using multiplex protein biomarkers	P. Gombrich	USA
--------	----------------------------------------------------------------------------------------------------------------------------	-------------	-----